Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
PNMA2 Biologics Sequence Review Report 2026: Paraneoplastic antigen Ma2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PNMA2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PLAUR Biologics Sequence Review Report 2026: Urokinase plasminogen activator surface receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PLAUR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PGF Biologics Sequence Review Report 2026: Placenta growth factor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PGF sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PEX5 Biologics Sequence Review Report 2026: Peroxisomal targeting signal 1 receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PEX5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PEAR1 Biologics Sequence Review Report 2026: Platelet endothelial aggregation receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PEAR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PDCD1LG2 Biologics Sequence Review Report 2026: Programmed cell death 1 ligand 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PDCD1LG2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PAGE4 Biologics Sequence Review Report 2026: P antigen family member 4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PAGE4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
OXGR1 Biologics Sequence Review Report 2026: 2-oxoglutarate receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OXGR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
OSMR Biologics Sequence Review Report 2026: Oncostatin-M-specific receptor subunit beta Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OSMR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
OR8G1 Biologics Sequence Review Report 2026: Olfactory receptor 8G1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OR8G1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
OR7D4 Biologics Sequence Review Report 2026: Olfactory receptor 7D4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OR7D4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
OR6A2 Biologics Sequence Review Report 2026: Olfactory receptor 6A2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of OR6A2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
208
209
210
211
212
>>
2260
>